Based on the results presented here, we postulate that the combination of disseminated disease (M1) at diagnosis, which is a well-established clinical prognostic factor in ES, with molecular evaluation of CDH2 expression may be a better predictor of poor prognosis in ES patients than the metastatic status alone. Here, CDH2 is linked to Ewing sarcoma.